Literature DB >> 4610386

Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer.

A H Glasgow, R B Nimberg, J O Menzoian, I Saporoschetz, S R Cooperband, K Schmid, J A Mannick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4610386     DOI: 10.1056/NEJM197412122912401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

1.  Soluble factors in immune sera of mice. I. Specific and non-specific suppressive activity.

Authors:  S T Lee; F Paraskevas
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

2.  Immunosuppression in chronic brucellosis.

Authors:  S C Chung
Journal:  Ir J Med Sci       Date:  1978-03       Impact factor: 1.568

3.  Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.

Authors:  T Hattori; T Nakajima; H Nakazato; T Tanabe; K Kikuchi; O Abe; T Kondo; T Taguchi; N Komi; K Sugimachi
Journal:  Jpn J Surg       Date:  1990-03

4.  A permeability-enhancing factor produced by tumor. The genesis of malignant effusions.

Authors:  R Stein-Werblowsky
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

5.  Inhibition of DNA synthesis in concanavalin A stimulated rat lymph node cells by serum from arthritic rats.

Authors:  L Binderup; E Bramm; E Arrigoni-Martelli
Journal:  Experientia       Date:  1977-03-15

6.  Role of a SER immune suppressor in immune surveillance.

Authors:  S K Oh; S Ross; J Walker; S Zeisel
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

7.  Response of cows with lymphoma to the intradermal injection of tumor cell antigens and phytohemagglutinin.

Authors:  R M Jacobs; V E Valli; B N Wilkie
Journal:  Can J Comp Med       Date:  1981-01

8.  Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma.

Authors:  P L Haslam; A Lukoszek; J A Merchant; M Turner-Warwick
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

9.  Autologous anticancer antigen preparation for specific immunotherapy in advanced cancer patients. A phase I clinical trial.

Authors:  C A Slanetz; D L McCollester; S Kanor
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

10.  [The influence on PHA-stimulation by inhibition of prostaglandin synthesis in vitro in patients with Hodgkin's disease (author's transl)].

Authors:  H W Pees; G Girmann; J Schwamborn
Journal:  Blut       Date:  1980-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.